US 11,771,488 B2
Ablation of lesions of low-medium depths using ultrahigh radiofrequency (RF) power for ultrashort durations
Assaf Govari, Haifa (IL); and Andres Altmann, Haifa (IL)
Assigned to Biosense Webster (Israel) Ltd., Yokneam (IL)
Filed by BIOSENSE WEBSTER (ISRAEL) LTD., Yokneam (IL)
Filed on Oct. 21, 2019, as Appl. No. 16/658,601.
Prior Publication US 2021/0113259 A1, Apr. 22, 2021
Int. Cl. A61B 18/12 (2006.01); A61B 18/14 (2006.01); A61B 90/00 (2016.01); A61B 17/00 (2006.01); A61B 18/00 (2006.01)
CPC A61B 18/1206 (2013.01) [A61B 18/1492 (2013.01); A61B 2017/0019 (2013.01); A61B 2018/00351 (2013.01); A61B 2018/00577 (2013.01); A61B 2018/00642 (2013.01); A61B 2018/00761 (2013.01); A61B 2018/00791 (2013.01); A61B 2090/065 (2016.02)] 16 Claims
OG exemplary drawing
 
1. A method of body tissue ablation, the method comprising:
(a) defining an ultrahigh-power ultrashort-duration (UPUD) radiofrequency (RF) ablation protocol that specifies an ablation signal having (i) a target ablation power of at least 400 Watts and (ii) comprising setting the pulse duration to between 0.5 second and 0.9 second, for creating a specified lesion in tissue in a body of a patient, the tissue including cardiac tissue;
(b) making contact between an ablation probe and the tissue; and
(c) using the ablation probe, applying the ablation signal to the tissue according to the UPUD RF ablation protocol, which delivers the ablation signal having the specified target ablation power and duration.